The multigene classifiers 95GC/42GC/155GC for precision medicine in ER‐positive HER2‐negative early breast cancer

Annual report of the Japanese Breast Cancer Society registry for 2016

(2020) Makoto Kubo et al.   Breast Cancer

A novel 95-gene signature (Curebest 95GC Breast) that predicts recurrence-risk in patients with ER-positive, HER2-negative, node-negative, early-stage primary invasive breast cancer with an intermediate Oncotype DX Recurrence Score.

(2019) Takeo Fujii et al.   JOURNAL OF CLINICAL ONCOLOGY

Construction of a novel multi-gene assay (42-gene classifier) for prediction of late recurrence in ER-positive breast cancer patients

(2018) Ryo Tsunashima et al.   BREAST CANCER RESEARCH AND TREATMENT

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

(2018) Joseph A. Sparano et al.   NEW ENGLAND JOURNAL OF MEDICINE

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

(2017) Hongchao Pan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Construction of multi-gene classifier for prediction of response to and prognosis after neoadjuvant chemotherapy for estrogen receptor positive breast cancers

(2015) Ryo Tsunashima et al.   CANCER LETTERS

Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer

(2015) Hiroko Yamashita et al.   Breast Cancer

Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

(2014) Pat Whitworth et al.   ANNALS OF SURGICAL ONCOLOGY

Comparison of efficacy of 95-gene and 21-gene classifier (Oncotype DX) for prediction of recurrence in ER-positive and node-negative breast cancer patients

(2013) Yasuto Naoi et al.   BREAST CANCER RESEARCH AND TREATMENT

Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China

(2012) Cong Xue et al.   CANCER SCIENCE

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

(2012) Christina Davies et al.   LANCET

Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients

(2010) Yasuto Naoi et al.   BREAST CANCER RESEARCH AND TREATMENT